Template:Malaria antibiotics: Difference between revisions

Revision as of 10:53, 20 March 2026

For specific dosing see the CDC Recommendations or call the Malaria CDC Hotline(855) 856-4713

Uncomplicated:
- No evidence of organ dysfunction
- Parasitemia <5%
- Able to tolerate PO
Hospitalize:
- Severe clinical manifestations in non-immune host for P. falciparum or P. knowlesi
Report to state health department
For non-pregnant patients (3 day course)
- Artemether + lumefantrine
- Artesunate + amodiaquine
- Artesunate + mefloquine
- Dihydroartemisinin + piperaquine
- Artesunate + sulfadoxine–pyrimethamine (SP)
For pregnant (1st trimester)
- Quinine + clindamycin x 7 days
Additional considerations
- Avoid artesunate + SP in HIV/AIDS patients taking co-trimoxazole
- Avoid artesunate + amodiaquine in HIV/AIDS patients taking efavirenz or zidovudine
- P. vivax and P. ovale have dormant hypnozoites in the liver which require treatment with primaquine phosphate for complete eradication

Do not delay treatment in the unstable patient if strong suspicion for malaria as initial smear may be falsely negative
Treatment (IV for ≥24 hours then 3 days PO course)
- Artesunate (IV)
  - Clears malaria faster than quinine
  - Distributed only through CDC
- Quinidine (IV) also appropriate choice; more available in US

@@ Line 29: / Line 29: @@
 ***Distributed only through CDC
 **Quinidine (IV) also appropriate choice; more available in US
+===Prophylaxis===
+*{{AntibioticDose|drug=Doxycycline|dose=100mg PO daily|context=Prophylaxis|disease=Malaria|population=Adult}}
+*{{AntibioticDose|drug=Doxycycline|dose=2.2 mg/kg/day PO daily (max 100mg/day), >8 years old|context=Prophylaxis|disease=Malaria|population=Pediatric}}
+===Suppression===
+*{{AntibioticDose|drug=Dapsone|dose=100mg PO weekly|context=Suppression|disease=Malaria|population=Adult}}